Noor Siddiqui (CEO of Orchid) and Harvard geneticist George Church argues that whole-genome sequencing (WGS) of embryos could dramatically alter how many people approach pregnancy, particularly via IVF and embryo screening. Siddiqui claims that by testing multiple embryos ahead of implantation, parents could largely eliminate monogenic (single-gene) diseases and reduce risks for common polygenic conditions—such as heart disease or diabetes—by 30-80%, depending on how many embryos are screened and how strong the genetic influences are. Church and others point out that costs have plunged since the Human Genome Project, making embryo WGS “several thousand dollars per embryo,” which many believe yields large cost-benefits in health, psychological, and familial terms. But critics warn of ethical concerns (including potential stigmatization and de facto eugenics), uncertain predictive power especially for polygenic risks, and issues of equity—access to the technology is expensive and currently limited to those who can afford IVF and extra screening.
Sources: Wired, Harvard Medical School
Key Takeaways
– Risk Reduction Potential vs. Predictive Uncertainty: Embryo whole-genome screening has promise to eliminate many single-gene genetic disorders and reduce risks for polygenic diseases, but the accuracy and predictive value—especially for polygenic traits—are not fully mature.
– Ethical, Social, and Access Concerns: There are serious ethical implications, including the possibility of stigmatization, eugenics debates, inequality (since only affluent patients currently have access), and cultural/social implications of selecting embryos.
– Cost Decline Enables Adoption, but Barriers Remain: Significant cost reductions in genome sequencing have made embryo screening more feasible, yet IVF plus WGS remains expensive, and regulatory, educational, and scientific validation hurdles need to be addressed before widespread implementation.
In-Depth
Over the past few years, advances in genome sequencing technology have dramatically shifted the ground under reproductive medicine. What used to be cutting-edge, highly specialized techniques—screening for a single gene mutation in high-risk families—are now evolving into more ambitious efforts: sequencing the whole genome of embryos in IVF to anticipate both monogenic (single-gene) conditions and polygenic risks (those influenced by many genes) such as for heart disease, diabetes, psychiatric illnesses, and more. At the recent WIRED Health event, Orchid Health’s Noor Siddiqui and geneticist George Church laid out a vision where screening embryos isn’t a rare procedure but may become standard practice, driven by lower costs and better risk models.
This potential is large. If you can screen multiple embryos, selecting one with fewer risk-alleles could reduce lifetime disease burdens nontrivially. Monogenic conditions can sometimes be avoided altogether; polygenic risk reductions are harder to nail precisely, but the estimates being floated—30-80% reduction in risk for certain diseases—are compelling. But it’s not just science; the ethical, social, and practical dimensions are hefty. Predictive power for complex traits remains imperfect. Many polygenic risk scores are based on population data that under-represent certain ethnic groups, which raises concerns about bias. And then there’s access: these services cost money—thousands per embryo on top of IVF costs—making them available only to relatively privileged segments.
Finally, there’s the question of what society wants. Should embryo screening for disease be embraced? What about non-disease traits? Where do we draw the line between medical prevention and eugenic selection? What regulation, oversight, and consent protocols should be in place? As the technology matures, public opinion seems cautiously favorable toward disease-related screening, but less so for trait enhancement. Education, regulation, and rigorous clinical validation will be key. Ultimately, whole-genome screening of embryos holds profound promise, but society must weigh that promise with humility, skepticism, and respect for diverse views.